Illumina, Inc. vs T-Mobile Us Inc — how do they compare? Illumina, Inc. trades at $278.17 (market cap $39.95B), while T-Mobile Us Inc trades at $148.58 (market cap $183.76B). The key difference: T-Mobile Us Inc is far larger — about 4.6× Illumina, Inc.'s market cap, and T-Mobile Us Inc pays a 2.73% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Illumina, Inc. for 83 Days and T-Mobile Us Inc for 84 Days on average.
| ILMN | TMUS | |
|---|---|---|
Market Cap | $39.95B | $183.76B |
Volume | 3,169,503 | 4,294,650 |
Sector | Health | Media |
52-Week High | $293.69 | $230.06 |
52-Week Low | $91.00 | $148.58 |
Typical Hold Time | 83 Days | 84 Days |
Enterprise Value | $41.31B | $300.37B |
Dividend Yield | — | 2.73% |
Signals from Pluang's Aura AI — not financial advice
ILMN trades at $264.40, down 1.25% on the day, but remains near its recent 52-week high of $278.99 (Defense World, 2026-10-01). The stock has surged 94.9% year-to-date (Zacks Investment Research, 2026-09-24), supported by strong earnings beats in recent quarters and a bullish technical trend. Fundamentals show a significant turnaround, with 2025 net income reaching $850 million after prior losses, though valuation ratios like a P/E of 49.36 are elevated. The pending inclusion in the S&P 500 (PRNewsWire, 2026-09-04) adds a positive catalyst.
The outlook is positive, driven by sequencing growth, AI integration in genomics, and improved profitability. However, risks include high valuation sensitivity, cost volatility, and competitive pressures in the life sciences sector. Analyst consensus is bullish with a 54% buy rating, but the average price target of $241 suggests limited near-term upside from current levels.
TMUS trades at $171.31, up 2.2% today, with a bullish technical signal and strong earnings beats in recent quarters. Revenue grew to $88.31B in 2025, with a net income margin of 11.45%, while the company announced a 15% dividend hike and AI-driven 5G network enhancements. Analyst consensus is strongly bullish with a $231.10 price target, though debt levels and competitive pressures remain considerations.
The outlook for TMUS is positive, driven by robust cash flow, strategic investments in network resilience, and favorable analyst sentiment. Key risks include high debt exposure and industry competition, but strong fundamentals and growth initiatives support a constructive view for long-term investors.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →Deutsche Telekom merged its T-Mobile USA unit with prepaid specialist MetroPCS in 2013, creating T-Mobile Us. Following the merger, the firm provided nationwide service in major markets but spottier coverage elsewhere. T-Mobile spent aggressively on low-frequency spectrum, well suited to broad coverage, and has substantially expanded its geographic footprint. This expansion, coupled with aggressive marketing and innovative offerings, produced rapid customer growth. With the Sprint acquisition, the firm's scale now roughly matches its larger rivals: T-Mobile now serves 71 million postpaid and 21 million prepaid phone customers, equal to around 30% of the U.S. retail wireless market. In addition, the firm provides wholesale service to resellers.
Read more on TMUS →